Viatris splashes out $350m on pair of Idorsia therapies

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus erythematosus (SLE) – that it thinks have the potential to become $1 billion-plus blockbusters.